Mental health-focused studio DeepWell has received clearance from the US’ Food and Drug Administration for its biofeedback SDK to be used therapeutically to help with stress reduction and high blood pressure.
This means DeepWell will be able to make the SDK available to other firms who might want to use it, with the end goal to “accelerate the commercialisation of video games and other immersive media as FDA-cleared digital therapeutics,” the announcement said.
It clarified that any media incorporating DeepWell technology will be available without needing a prescription.
